ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials

Esteva, Andre*; Feng, Jean; van der Wal, Douwe; Huang, Shih-Cheng; Simko, Jeffry P.; DeVries, Sandy; Chen, Emmalyn; Schaeffer, Edward M.; Morgan, Todd M.; Sun, Yilun; Ghorbani, Amirata; Naik, Nikhil; Nathawani, Dhruv; Socher, Richard; Michalski, Jeff M.; Roach, Mack, III; Pisansky, Thomas M.; Monson, Jedidiah M.; Naz, Farah; Wallace, James; Ferguson, Michelle J.; Bahary, Jean-Paul; Zou, James; Lungren, Matthew; Yeung, Serena; Ross, Ashley E.; Sandler, Howard M.; Tran, Phuoc T.西北大学
npj Digital Medicine2022-6-8DOI: 10.1038/s41746-022-00613-w
61被引10阅读
引用收藏
分享

摘要

Prostate cancer is the most frequent cancer in men and a leading cause of cancer death. Determining a patient's optimal therapy is a challenge, where oncologists must select a therapy with the highest likelihood of success and the lowest likelihood of toxicity. International standards for prognostication rely on non-specific and semi-quantitative tools, commonly leading to over- and under-treatment. Tissue-based molecular biomarkers have attempted to address this, but most have limited validation in prospective randomized trials and expensive processing costs, posing substantial barriers to widespread adoption. There remains a significant need for accurate and scalable tools to support therapy personalization. Here we demonstrate prostate cancer therapy personalization by predicting long-term, clinically relevant outcomes using a multimodal deep learning architecture and train models using clinical data and digital histopathology from prostate biopsies. We train and validate models using five phase III randomized trials conducted across hundreds of clinical centers. Histopathological data was available for 5654 of 7764 randomized patients (71%) with a median follow-up of 11.4 years. Compared to the most common risk-stratification tool-risk groups developed by the National Cancer Center Network (NCCN)-our models have superior discriminatory performance across all endpoints, ranging from 9.2% to 14.6% relative improvement in a held-out validation set. This artificial intelligence-based tool improves prognostication over standard tools and allows oncologists to computationally predict the likeliest outcomes of specific patients to determine optimal treatment. Outfitted with digital scanners and internet access, any clinic could offer such capabilities, enabling global access to therapy personalization.

学科与关键词

关键词
INTEROBSERVER REPRODUCIBILITYARTIFICIAL-INTELLIGENCEANDROGEN SUPPRESSIONRADIOTHERAPYCLASSIFICATIONDEPRIVATIONBIOMARKERSGUIDELINESCARCINOMADURATION
相关
加载中…
  • Artificial intelligence applications in prostate cancer
    Baydoun, Atallah; Jia, Angela Y. Y.; Zaorsky, Nicholas G. G.; Kashani, Rojano; Rao, Santosh; Shoag, Jonathan E. E.; Vince, Randy A. A.; Bittencourt, Leonardo Kayat; Zuhour, Raed; Price, Alex T. T.; Arsenault, Theodore H. H.; Spratt, Daniel E. E.*PROSTATE CANCER AND PROSTATIC DISEASES, 2024, 27(1): 37-45.被引 26
  • The Application of Artificial Intelligence in Prostate Cancer Management-What Improvements Can Be Expected? A Systematic Review
    Thenault, Ronan*; Kaulanjan, Kevin; Darde, Thomas; Rioux-Leclercq, Nathalie; Bensalah, Karim; Mermier, Marie; Khene, Zine-eddine; Peyronnet, Benoit; Shariat, Shahrokh; Pradere, Benjamin; Mathieu, RomainApplied Sciences-Basel, 2020, 10(18): 6428.被引 10
  • An international multi-institutional validation study of the algorithm for prostate cancer detection and Gleason grading
    Tolkach, Yuri*; Ovtcharov, Vlado; Pryalukhin, Alexey; Eich, Marie-Lisa; Gaisa, Nadine Therese; Braun, Martin; Radzhabov, Abdukhamid; Quaas, Alexander; Hammerer, Peter; Dellmann, Ansgar; Hulla, Wolfgang; Haffner, Michael C.; Reis, Henning; Fahoum, Ibrahim; Samarska, Iryna; Borbat, Artem; Pham, Hoa; Heidenreich, Axel; Klein, Sebastian; Netto, George; Caie, Peter; Buettner, Reinhardnpj Precision Oncology, 2023, 7(1): 77.被引 8
查看全部 →

发表信息

论文状态
公开发表
期刊
npj Digital Medicine
发表日期
2022-06-08
卷期
第 5 卷, 第 1 期
页码
71
DOI
10.1038/s41746-022-00613-w
期刊等级
1区
成果收录
SCIE
资助标注
National Cancer Institute (NCI) [U10CA180868, U10CA180822, UG1CA189867, U24CA196067]; Artera, Inc.

作者

  • E

    Esteva, Andre (通讯) (第一作者)

  • F

    Feng, Jean

查看全部 32 位作者收起作者
  • v

    van der Wal, Douwe

  • H

    Huang, Shih-Cheng

  • S

    Simko, Jeffry P.

  • D

    DeVries, Sandy

  • C

    Chen, Emmalyn

  • S

    Schaeffer, Edward M.

    northwestern univ

  • M

    Morgan, Todd M.

  • S

    Sun, Yilun

  • G

    Ghorbani, Amirata

  • N

    Naik, Nikhil

  • N

    Nathawani, Dhruv

  • S

    Socher, Richard

  • M

    Michalski, Jeff M.

  • R

    Roach, Mack, III

  • P

    Pisansky, Thomas M.

  • M

    Monson, Jedidiah M.

  • N

    Naz, Farah

  • W

    Wallace, James

  • F

    Ferguson, Michelle J.

  • B

    Bahary, Jean-Paul

  • Z

    Zou, James

  • L

    Lungren, Matthew

  • Y

    Yeung, Serena

  • R

    Ross, Ashley E.

    northwestern univ

  • S

    Sandler, Howard M.

  • T

    Tran, Phuoc T.

  • S

    Spratt, Daniel E.

  • P

    Pugh, Stephanie

  • F

    Feng, Felix Y.

  • M

    Mohamad, Osama

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417